Physiomics. Rational Therapeutics

Our technology has conferred many benefits to our partners:

Physiomics has been providing continued support to Lilly's oncology program since 2007, studying cancer cellular processes for drugs targeting the cell cycle. It has also licensed customized versions of its ModelPlayer to Lilly, allowing them to perform their own simulations of anticancer agents using Physiomics’ models.

In 2011, Physiomics and Phramacometrics have entered into an agreement to develop a new anti-cancer drug regimen and combination database. This database will be ultimately marketed to clinicians and researchers in oncology, as well as used to supplement and enhance Physiomics' service.

In 2010, Physiomics has entered into a collaboration with Sareum, in which Physiomics provides in silico simulations to support Sareum’s cancer drug joint research program with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited (CRT).

In 2007, Physiomics and the Institute of Life Science at Swansea University (ILS) have entered into a collaborative research program. The goal of this collaboration was to validate Physiomics models and technology on supercomputers, such as the High Performance Computer “Blue C” available at the ILS, one of the most powerful computers in the world dedicated to Life Science and result of a collaboration between the University, the Welsh Assembly Government and computer giant IBM. This has reinforced Physiomics’ modelling framework and helped to address the ever increasing computing requirements in the field of System Biology.

Our apoptosis model technology has supported both “no-go” and “go” decisions for therapeutic targets. George Morris, Chief Development Officer of ValiRx, said: "Physiomics service and technology is absolutely superb, we (ValiRx) have just had some work carried out and it has saved us very significant amounts of development money and time. This is the first time the research has been done this way…"

We are developing our technology with both industrial and academic partners across the European Union: as part of the TEMPO project (October 2006 – December 2009) we have developed combined pharmacokinetic-pharmacodynamic models of cancer processes in order to determine optimal chronotherapeutic scheduling for cell cycle inhibitors. The aim is that this will support clinical trials in the future.

We have also been working with other industrial partners to develop and enhance our technological capability. In 2004, Physiomics entered into a strategic alliance with Bayer Technology Services GmbH (BTS) to integrate PK-Sim^® with its novel biological simulations.